ARTICLE | Emerging Company Profile
Immunology company’s lead program targets a specific fibroblast subpopulation to induce formation of tertiary lymphoid structures in solid tumors
By Richard Guy, Biopharma Analyst
July 10, 2024 11:28 PM UTC
Immunology company Mestag believes that fibroblasts have been long overlooked as therapeutic targets and can be leveraged to treat cancer and inflammatory diseases. The company has raised $45 million and presented data for its lead program to treat solid tumors at AACR.
CEO Susan Hill told BioCentury that Cambridge, U.K.-basaed Mestag Therapeutics Ltd. was founded by a group of five scientists who had identified a distinct subpopulation of fibroblasts capable of inducing the formation of tertiary lymphoid structures (TLSs) — vascularized hubs of lymphocyte interaction and activation that arise from interactions between activated T and B cells and cytokines CCL19, CCL21 and CXCL13. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652070/mestag-attacking-tumors-from-within